TY - JOUR
T1 - Ultrasound-guided surgery for palpable breast cancer is cost-saving: Results of a cost-benefit analysis
AU - Haloua, M.H.
AU - Krekel, N.M.A.
AU - Coupe, V.M.H.
AU - Bosmans, J.E.
AU - Cardozo, A.M.F.L.
AU - Meijer, S.
AU - van den Tol, M.P.
PY - 2013
Y1 - 2013
N2 - Ultrasound-guided surgery (USS) has recently been proven to result in a significant reduction of tumour-involved surgical margins, for patients with palpable invasive breast cancer. The objective of this economic evaluation alongside a randomised trial was to evaluate the costs and benefits of USS compared to palpation-guided surgery (PGS). The hospital perspective was used. On the cost side of the analysis, resource use related to baseline treatment was taken into account and on the benefit side, resource use related to additional treatments was included. On the cost side, the difference in costs per patient was €193 (95% CI €153-€233) with higher costs in the USS group. On the benefit side, the difference in costs per patient was -€349 (95% CI -€591 to -€103) with higher costs in the PGS group. This resulted in a cost decrease of -€154 (95% CI -€388 to €81) in the USS group compared to the PGS group. Intra-operative use of a US system during BCS reduces the rate of tumour-involved margins and thereby the costs of additional treatments. © 2013 Elsevier Ltd.
AB - Ultrasound-guided surgery (USS) has recently been proven to result in a significant reduction of tumour-involved surgical margins, for patients with palpable invasive breast cancer. The objective of this economic evaluation alongside a randomised trial was to evaluate the costs and benefits of USS compared to palpation-guided surgery (PGS). The hospital perspective was used. On the cost side of the analysis, resource use related to baseline treatment was taken into account and on the benefit side, resource use related to additional treatments was included. On the cost side, the difference in costs per patient was €193 (95% CI €153-€233) with higher costs in the USS group. On the benefit side, the difference in costs per patient was -€349 (95% CI -€591 to -€103) with higher costs in the PGS group. This resulted in a cost decrease of -€154 (95% CI -€388 to €81) in the USS group compared to the PGS group. Intra-operative use of a US system during BCS reduces the rate of tumour-involved margins and thereby the costs of additional treatments. © 2013 Elsevier Ltd.
UR - https://www.scopus.com/pages/publications/84877153431
UR - https://www.scopus.com/inward/citedby.url?scp=84877153431&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2013.02.002
DO - 10.1016/j.breast.2013.02.002
M3 - Article
SN - 0960-9776
VL - 22
SP - 238
EP - 243
JO - Breast
JF - Breast
IS - 3
ER -
